Genomic biomarkers of sensitivity to molecularly targeted drugs used to treat NSCLC include mutations or rearrangements in EGFR (3), ALK (4), MET (5), ROS (6) and RET (7), and KRAS (8). This evidence concerns the gene EGFR and non-small cell lung carcinoma.